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Abstract. The mutations of MLH1 and MSH2 have been
reported to be responsible for malignant transformation and
tumour progression in several sporadic tumours. Eighty-six
primary malignant melanomas with known follow-up were
investigated. Point mutations of DNA mismatch repair MLH1
and MSH2 in malignant melanomas were not found. Exon 12
(MSH2) was not present in 26 out of the 86 melanomas and
exon 13 (MSH2) was lost in 25 of the tumours. The loss of
exon 15 (MLH1) was observed in 22 out of the 86 tumours
and the loss of exon 16 (MLH1) in 24 melanomas. The loss
of exons correlated strongly with the loss of MLH1 and MSH2
protein expression. In multivariate analysis, including all 4
exons and expressions of MLH1 and MSH2, prognostic
significance was found only for loss of exon 12 (MSH2) and
loss of exon 15 (MLH1).
DNA mismatch repair plays an important role in the
preservation of genetic integrity from bacteria to mammals.
For the first time, the defects of the repair genes MLH1 and
MSH2 have been demonstrated in hereditary nonpolyposis
colon cancer(HNPCC) (1-5). Subsequently, it was shown
that HNPCC is caused by germ-line mutations in the human
homologues of the bacterial and yeast MutS and MutL
mismatch repair genes, including hMSH2 on chromosome
2p16 and hMLH1 on 3p21(6-9). Recently, the defects of the
DNA mismatch repair system were reported to be
responsible for malignant transformation and tumour
progression in several sporadic tumours, including
colorectal cancer, pancreatic and gastric carcinoma,
endometrial, prostatic and breast cancer (10-12). In
malignant melanomas, the DNA mismatch repair system
has not yet been investigated in detail. The main goal of this
study was to examine the presence of MSH2 and MLH1
mutations and their eventual prognostic outcome in a
representative collection of malignant melanomas with
known follow-up. 
Materials and Methods
Patients. The material investigated consisted primarily of 106
malignant melanomas. It was possible to isolate DNA from 86
cases (pTis-12, pT1-4, pT2-18, pT3-23 and pT4-29) obtained from
39 females and 47 males. The melanomas were located as follows:
head and neck 17, trunk 38, upper extremity 22, lower extremity 9.
Twenty-two cases were classified as superficially spreading
melanomas and 64 were nodular. 
PCR analysis of MLH1 and MSH2 exons. The histological material
was cut into sterile Eppendorf microfuge tubes. After washing once
with xylene and twice with ethanol (96%) to remove xylene rests,
the cells and cellular debris were obtained by centrifugation at 
500 rpm at 4ÆC. The DNA was isolated from the samples with a
QIAamp DNA Mini Kit (Qiagen, Germany). Five Ìl of extracted
DNA were used for PCR performed on a thermal cycler model 480
(Perkin Elmer, Weiterstadt, Germany). Each PCR was performed
on a 50-Ìl mixture, in a thin-walled reaction tube, consisting of 1
unit Tfl DNA polymerase, polymerase buffer (BIOzym, Hessisch
Oldendorf, Germany) and 20 ÌM of each dNTP. The mixture was
overlaid with mineral oil (Sigma, Munich, Germany). The PCR
primers were synthesised by MWG (Ebersberg, Germany) and
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added at a final concentration of 40 pmol/l per assay. Standard
precautions against cross-contamination were taken (13).
The presence of non-degraded DNA in the samples was tested by
a semi-nested PCR specific to the human ‚-globin gene. ‚-globin
DNA was amplified using the primer pairs 5’-ATGGTGCACCT
GACTCCTGAGG-3’ (sense 1)/5’-GCCATCACTAAAGGCACC
GAGC-3’ (anti-sense) and 5’-CTGTGGGGCA AGGTGAACG-3’
(sense 2)/ anti-sense. The sense 2/anti-sense primers yield a 290-bp
product. For amplification, the test tubes were heated to 95ÆC for 
7 min, followed by 40 cycles at 95ÆC for 45 sec, 60ÆC for 20 sec and
72ÆC for 1 min and a final extension at 72ÆC for 7 min. For the
second PCR run, 1-2 Ìl of the first run PCR product was used. The
PCR conditions in runs 1 and 2 were identical.
Only ‚-globin-positive cases were used for the nested PCR
analysis of the MLH1 and MSH2 exons. Exon 12 of MSH2 was
amplified with the help of the following primers: 5’-TTTC
TGTTTTTATTTTTTTACAGG-3’ (forward primer), 5’-AAACG
TTACCCCCACAAAG-3’ (reverse primer). For the analysis of
exon 13 of MSH2, the following primers were applied: 5’-CTAA
CAATCCATTTATTAGTAGC-3’ (forward primer) and 5’-CATTT
CTATCTTCAAGGGACTAGGA-3’ (reverse primer). Exon 15 of
MLH1 was investigated applying the primers: 5’-ATTTGTCCC
AACTGGTTGTATCTC-3’(forward primer) and 5’-ACTATACAA
TACAGCAACTATCCT-3’(reverse primer). Exon 16 of MLH1
was analysed using the primers: 5’-GCTTGCTCCTTCATGTT
CTTG-3’(forward primer) and 5’-CACCCGGCTGGAAATTT
TAT-3’(reverse primer). For the amplification of MLH1 exons 15
and 16 and MSH2 exons 12 and 13, the test tubes were heated to
95ÆC for 7 min, followed by 40 cycles at 95ÆC for 45 sec, 60ÆC for
20 sec and 72ÆC for 1 min and a final extension at 72ÆC for 7 min.
The aliquots of the final reaction product were analysed by
electrophoresis in 3% agarose gels containing ethidium bromide
and visualised under ultraviolet light. The amplified fluorescent
PCR products were mixed with TAMRA 350-internal size standard
(Perkin-Elmer, Weiterstadt, Germany) and analysed by
GENESCAN analysis software 672 on the automatic DNA analyzer
(ABI 310, Weiterstadt, Germany). 
Protein expression of MLH1 and MSH2. The following antibodies
were applied to demonstrate DNA mismatch repair gene
expression: a) N-20, rabbit polyclonal antibody against the epitope
corresponding to an amino acid sequence mapping at the amino
terminus of hMSH2 of human origin (Santa Cruz Biotechnology
Inc., Heidelberg, Germany); b) C-20, rabbit polyclonal antibody
against the epitope corresponding to an amino acid sequence
mapping at the carboxy terminus of hMLH1 of human origin
(Santa Cruz Biotechnology, Inc.).
The immunohistochemical reactions in the paraffin-embedded
tumour tissue were carried out using the Stravigen Multilink kit
(Biogenex Laboratories, Hamburg, Germany). The histological
sections were mounted on uncoated slides and were deparaffinated
by xylol and then transferred to a descending alcohol series and
rinsed with distilled water. Before incubation with the primary
antibodies, the sections were heated for 10 min on a hot-plate
(85ÆC) in citrate buffer (pH=6). Afterwards, incubation with the
primary antibodies was carried out overnight at 4ÆC at an antibody
concentration of 1:50. The histological specimens were then rinsed
with Tris buffer solution and incubated at room temperature with
the link (Stravigen Multilink, Biogenex Laboratories) for 45 min.
After the detection reaction had been performed using a label
(Stravigen Multilink, Biogenex Laboratories) in combination with
chromogen fast red (Biogenex Laboratories, Hamburg, Germany),
the nuclei were counterstained with hematoxylin. In the control
reactions, the primary antibodies were omitted. The sections were
evaluated by the CAS200 image analysis (Becton-Dickinson,
Hamburg, Germany) system and the results were expressed as
percentages of immunolabelled cell-indices.
Statistics. The data were analysed using the statistical analysis system
(SPSS, Version 7.5) on an IBM-compatible PC under Windows NT
4.0. The data were first scanned into the spread-sheet (Microsoft
Excel 97), where they were made available to the statistics program
via an ODBC driver (open database connectivity).
The Kaplan-Meier method was employed to calculate the
survival rates (14). The significance of differences in the survival
curves was calculated with log-rank tests. Cox regression was the
multivariate method used for predicting the survival rate based on
several parameters (15). This method estimates the regression
coefficients that make it possible to form a prediction equation.
The Cox regression was used repeatedly to explore the set of data.
Parameters were selected and the dataset was modelled using the
methods offered by SPSS forward selection and backward
selection. The first method adds parameters to a survival prediction
model until the exclusion criterion is reached. By contrast,
backward selection eliminates parameters from the model until the
inclusion criterion is reached. The terminal criteria (for inclusion
or exclusion) was the likelihood ratio based on partial likelihood
estimators. In general, the Cox regression helps provide a formula
for predicting the survival and testing the significance of individual
predictors. 
Results
Exonic deletions of MSH2 and MLH1. Exon 12 of MSH2 was
present in 60 cases investigated and lost in 26 melanomas.
Exon 13 of MSH2 was positive in 61 tumours and negative
in 25 melanomas (Figure 1). Exon 15 of MLH1 was found
to be present in 64 melanomas, but it was not possible to
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Figure 1. Positive PCR product for exon 13 of MSH2 in malignant
melanomas. Exon 13 presence was found in cases 1-7 and 9 and lost in
case 8.
detect its presence in 22 of the tumours investigated. Exon
16 of MLH1 was observed in 62 tumours and lost in 24
melanomas. 
Kaplan-Meier survival curves of melanomas, with and without
exonic deletions. When comparing the Kaplan-Meier survival
curves for exon 12 and exon 13 (MSH2)-positive and 
- negative melanomas the difference between them was
significant (p=0.013) (Figure 2a). In contrast, the difference
for exon 15 and exon 16 (MLH1)-positive and -negative
melanomas was highly significant (p=0.006) (Figure 2b).
Protein expression of MSH2 and MLH1. MSH2 expression
oscillated between 0 and 98%. Significant and highly
significant relationships between MSH2 expression and the
loss of exons 12 and 13 (MSH2) are demonstrated in Figure
4a. MLH1 expression ranged between 0 and 96% (Figure
3). The relationship between MLH1 expression and loss of
exons 15 and 16 (MLH1) is shown in Figure 4b. 
Multivariate analyses (Cox regression model forward and
backward). In forward and backward selection, including the
loss of all 4 exons and the expression of MSH2 and MLH1,
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Figure 2. a. Kaplan-Meier survival curves of exon 12 and exon 13
(MSH2)-positive (E=1) and -negative (E=0) melanomas. Survival time
expressed in months. b. Kaplan-Meier survival curves of exon 15 and exon
16 (MLH1)-positive (E=1) and -negative (E=0) melanomas. Survival
time expressed in months.
Figure 3. Nuclear reaction product of MLH1 in malignant melanoma,
x400.
Figure 4. a. Boxplot demonstrating the MSH2 expression in exon 12 and
exon 13 (MSH2)-positive (E=1) and -negative (E=0) melanomas. Y-axis:
percentage of MSH2-positive cells. b. Boxplot showing the MLH1 reactivity
in exon 15 and exon 16 (MLH1)-positive (E=1) and -negative (E=0)
melanomas. Y-axis: percentage of MLH1-positive cells.
only the loss of exon 12 of MSH2 (p<0.001, coefficient of
regression 0.8574, change of risk +136%, confidence limits
+56% to +256%) and the loss of exon 15 of MLH1
(p=0.024, coefficient of regression 0.431, change of risk
+54%, confidence limits +6% to +124%) had a significant
effect on patient survival.
Point mutations of MLH1 and MSH2. No point mutations of
the DNA mismatch repair genes, MLH1 and MSH2, were
found in malignant melanomas.
Discussion
We analysed four of the most frequently mutated exons of
MLH1 and MSH2 in 86 cases of malignant melanomas with
known follow-up. Although there was a visible trend toward
the loss of all 4 exons, prognostic significance was only
defined for the loss of exon 12 of MSH2 and the loss of
exon 15 of MLH1. Point mutations in MSH2 and MLH1 in
malignant melanomas were not found. 
Previous studies have suggested that the MSH2-MLH1-
PMS1 pathway of mismatch repair primarily corrects
insertions or deletions of one or two units of dinucleotide
repeats (16). Given the importance of genomic instability in
generating the multiple mutations necessary for multi-step
tumorigenesis, mutator phenotype tumours might be
expected to have accelerated progression. Indeed, HNPCC
tumours often give the clinical impression of quicker
progression. An increase in mutation rate might be expected
to accelerate progression to the same end-point, because
fewer divisions are needed to alter the usual genetic
transformation barriers. 
In malignant melanomas, not the mutation phenotype,
but the phenomenon of exonic deletions seems to play a
more important role concerning the prediction of patient
prognosis. In our previous study, we demonstrated that the
loss of the protein expression of repair genes, especially
MLH1, MSH2, Ku70, Ku80 and APC, negatively influenced
the prognosis in melanoma patients (17-24). The loss of
gene expression was demonstrated to be functionally related
to either the methylation of the promotor region or to
mutational changes (25-26). Our study demonstrated some
significant and, even partly, highly significant relationships
between the loss of MLH1 and MSH2 protein expression
and exonic deletions of these genes. 
Multivariate analysis demonstrated that the loss of exon
12 of MSH2 and the loss of exon 15 of MLH1 have a
marked prognostic significance for malignant melanomas.
Our results correspond with cytogenetic anomalities of the
chromosomes on which MLH1 and MSH2 are located.
Chromosome 2 is often translocated, as reported for
melanoma brain metastases (27), and chromosome 3 could
be lost, as reported for uveal melanomas (28-30).
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